Effect of GnRH agonist therapy on the expression of human heat shock protein 70 in eutopic and ectopic endometria of women with endometriosis

Imamura T, Takehito Imamura, Khaleque N Khan, Khaleque Newaz Khan, Khan KN, Akira Fujishita, Fujishita A, Michio Kitajima, Kitajima M, Hiraki K, Koichi Hiraki, Ishimaru T, Tadayuki Ishimaru, Masuzaki H, Hideaki Masuzaki
European journal of obstetrics, gynecology, and reproductive biology · 2014 · vol. 180 , pp. 16–23 · doi:10.1016/j.ejogrb.2014.06.002 · PMID:25016551 · W2000312919
article OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study investigated the impact of GnRH agonist therapy on heat shock protein 70 expression in both eutopic and ectopic endometrial tissues from women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectivesHuman heat shock protein 70 (HSP70) has been reported to enhance Toll-like receptor 4-mediated pelvic inflammation and growth of endometriotic cells. However, information on tissue expression of HSP70 before and after treatment with estrogen suppressing agent is scanty. Here, we investigated tissue expression HSP70 in the eutopic/ectopic endometria of gonadotropin-releasing hormone agonist (GnRHa)-treated and -non-treated women with endometriosis.Study designBiopsy specimens were collected from peritoneal lesions, cyst walls, and corresponding endometria of 20 women with peritoneal endometriosis, 35 women with ovarian endometrioma, and 15 control women during laparoscopy. Fifteen women with ovarian endometrioma were treated with GnRHa for a variable period of 4-6 months before laparoscopy. The immunoexpressions of HSP70 and CD68-positive macrophages (Mφ) in endometria, peritoneal lesions, and cyst walls were examined by immunohistochemistry. The immunoreactivity of HSP70 in tissues was analyzed by quantitative-histogram (Q-H) score.ResultsTissue expression of HSP70 was found to be the highest in the menstrual phase than in other phases of the menstrual cycle. A significantly higher immunoreactivity of HSP70 was found in the eutopic endometria of women with peritoneal and ovarian endometriosis than in controls and in opaque red lesions than in other peritoneal lesions. A significant correlation between Q-H scores of HSP70 and CD68-positive Mφ numbers was found in the endometria derived from women with peritoneal endometriosis (r=0.481) and in ovarian endometrioma (r=0.560) but not in control women. The Q-H scores of HSP70 expression were significantly lower in cyst walls, coexisting peritoneal lesions and corresponding endometria of women with ovarian endometrioma after GnRHa treatment comparing to similar tissues derived from women without GnRHa treatment.ConclusionThese results suggest that as a marker of tissue stress reaction, immunoexpression of HSP70 was highly increased in pathological lesions and endometria of women with endometriosis and had a significant correlation with tissue inflammatory reaction. The higher tissue expression of HSP70 can be effectively suppressed after GnRHa treatment.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometrium Gonadotropin-Releasing Hormone HSP70 Heat-Shock Proteins Menstrual Cycle Ovarian Diseases Peritoneal Diseases Adult Case-Control Studies Endometriosis Endometriosis Endometrium Endometrium Female Gonadotropin-Releasing Hormone HSP70 Heat-Shock Proteins HSP70 Heat-Shock Proteins Humans Immunohistochemistry Menstrual Cycle

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

Cited by (9)

Source provenance

europepmc
last seen: 2026-08-05T06:13:34.187606+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:22.440000+00:00
License: CC0 · commercial use OK